[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-330911-105":59,"doc-detail-330911-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunotherapy-prognostic-and-tumor-biomarker-based-on-pancancer-analysis-smarcd3-research-paper","Immunotherapy, prognostic, and tumor biomarker based on pancancer analysis, SMARCD3 - Research Paper","","Background: SMARCD3 is implicated in cancer biology and has been reported to influence outcomes in specific malignancies. This study examines whether SMARCD3 participates across multiple cancer types and assesses its potential prognostic and immunotherapy relevance. Methods: Using UCSC Xena data covering 33 malignancies, the work evaluates SMARCD3 expression, survival associations, and links to tumor microenvironment features via CIBERSORT and ESTIMATE, with immune gene and pathway exploration through TISIDB and GSEA. MSI, TMB, and immunotherapy response analyses further test impact on treatment efficacy. Results: SMARCD3 shows cancer-dependent heterogeneity, acts as a risk factor in several cancers, correlates with immune and chromatin-related pathways, and may represent an immunotherapy target. Conclusion: Findings indicate SMARCD3 as a biomarker tied to prognosis and immunotherapy response, supporting follow-up research.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunotherapy-prognostic-and-tumor-biomarker-based-on-pancancer-analysis-smarcd3-research-paper/330911/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunotherapy-prognostic-and-tumor-biomarker-based-on-pancancer-analysis-smarcd3-research-paper/330911.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this pancancer study on SMARCD3?","Question",{"text":112,"@type":113},"To systematically evaluate SMARCD3 across cancers and determine its potential involvement as a prognostic factor and immunotherapy-relevant biomarker.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which datasets and analytical tools were used to assess SMARCD3?",{"text":117,"@type":113},"Gene expression, survival, and clinical data from the UCSC Xena database were used; tumor microenvironment estimation involved CIBERSORT and ESTIMATE, immune-gene analysis used TISIDB, and pathway relationships were tested with GSEA.",{"name":119,"@type":110,"acceptedAnswer":120},"How does SMARCD3 relate to prognosis and immunotherapy response according to the results?",{"text":121,"@type":113},"SMARCD3 shows heterogeneity in expression and prognostic value across cancer types, acts as a risk factor in multiple cancers, and is associated with pathways and immune response features. Immunotherapy analysis suggests SMARCD3 may serve as a potential immunotherapy target.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},330911,1790197077,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 11  \nResearch Paper  \nImmunotherapy, prognostic, and tumor biomarker based on pancancer analysis, SMARCD3  \nZishun Guo1, Bingji Cao2, Zhuozheng Hu1, Jiajun Wu1, Weijun Zhou1, Wenxiong Zhang1, Zhihua Shi2  \n1 Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China  \n2 Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  \nCorrespondence to: Zhihua Shi; email: [shibukedang2000@163.com](shibukedang2000@163.com), [https://orcid.org/0000-0003-0328-9527](https://orcid.org/0000-0003-0328-9527)[ ](https://orcid.org/0000-0003-0328-9527)[Keywords:](Keywords: SMARCD3)[ SMARCD3](Keywords: SMARCD3), pan-cancer analysis, immunotherapy, prognostic, biomarker  \nReceived: November 28, 2023 Accepted: April 10, 2024 Published: June 11, 2024  \nCopyright: © 2024 Guo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nBackground: SMARCD3 has recently been shown to be an important gene affecting cancer, playing an important role in medulloblastoma and pancreatic ductal adenocarcinoma. Therefore, we conducted this research to investigate the potential involvement of SMARCD3 across cancers and to offer recommendations for future studies.  \nMethods: Utilizing information on 33 malignancies in the UCSC Xena database, SMARCD3 expression and its prognostic value were assessed. The tumor microenvironment was evaluated with the “CIBERSORT” and“ESTIMATE” algorithms. SMARCD3 and immune-related genes were analyzed using the TISIDB website. The pathways related to the target genes were examined using GSEA. MSI (microsatellite instability), TMB (tumor mutational burden), and immunotherapy analysis were used to evaluate the impact of target genes on the response to immunotherapy.  \nResults: There is heterogeneity in terms of the expression and prognostic value of SMARCD3 among various cancers, but it is a risk factor for many cancers including uterine corpus endometrial cancer (UCEC), renal clear cell carcinoma (KIRC), and gastric adenocarcinoma (STAD) . GSEA revealed that SMARCD3 is related to chromatin remodeling and transcriptional activation, lipid metabolism, and the activities of various immune cells. The TMB and MSI analyses suggested that SMARCD3 affects the immune response efficiency of KIRC, LUAD and STAD. Immunotherapy analysis suggested that SMARCD3 may be a potential immunotherapy target. RT-qPCR demonstrated the variation in SMARCD3 expression in KIRC, LUAD, and STAD.  \nConclusion: Our study revealed that SMARCD3 affects the prognosis and immunotherapy response of some tumors, providing a direction for further research on this gene.  \nINTRODUCTION  \nEvery year, cancer morbidity and death rates increase worldwide, resulting in significant social and economic burdens [1–3] . In the exploration of cancer treatment methods, the exploration of new tumor markers and targets is becoming increasingly important, and precise treatment strategies targeting tumor markers have  \nbecome an important research direction for cancer treatment [4, 5] .  \nSMARCD3 (SWI/SNF connected, matrix related, actindependent regulator of chromatin, subfamily d, member 3) is a gene with great potential value. It has been demonstrated to have a significant impact on chromatin remodeling, DNA damage repair, and other processes.  \n10074  \nWhen SMARCD3 is silenced in mice, it leads to abnormalities in heart development [6] . SMARCD3 genetic polymorphisms are strongly linked to DNA damage levels in the Chinese population [7] .  \nRecently, researchers have discovered that it also plays a role in cancer. SMARCD3 was shown to control epithelial–mesenchymal transition in breast cancer cells and epithelial tissu","cbCaisQ5pFGQZWPI","https://ap.wps.com/l/cbCaisQ5pFGQZWPI","pdf",5299217,34,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Materials and Methods\n## Pancancer data download\n## ssGSEA gene activity analysis\n## Pancancer prognostic analysis\n## Tumor microenvironment","[{\"question\":\"What is the main purpose of this pancancer study on SMARCD3?\",\"answer\":\"To systematically evaluate SMARCD3 across cancers and determine its potential involvement as a prognostic factor and immunotherapy-relevant biomarker.\"},{\"question\":\"Which datasets and analytical tools were used to assess SMARCD3?\",\"answer\":\"Gene expression, survival, and clinical data from the UCSC Xena database were used; tumor microenvironment estimation involved CIBERSORT and ESTIMATE, immune-gene analysis used TISIDB, and pathway relationships were tested with GSEA.\"},{\"question\":\"How does SMARCD3 relate to prognosis and immunotherapy response according to the results?\",\"answer\":\"SMARCD3 shows heterogeneity in expression and prognostic value across cancer types, acts as a risk factor in multiple cancers, and is associated with pathways and immune response features. Immunotherapy analysis suggests SMARCD3 may serve as a potential immunotherapy target.\"}]","Immunotherapy, prognostic, and tumor biomarker based on pancancer analysis, SMARCD3 - Research Paper | PDF",1789990680,86]